ENO1 and glioblastoma: Consistently, TAK-242-mediated TLR4 inhibition attenuated PI3K-Akt activation (Fig. 5K), suggesting ENO1 may activate additional signaling cascades beyond PI3K/Akt to contribute to GBM aggressiveness.